Kairos Pharma (NYSEAMERICAN:KAPA) Stock Price Up 16.9% – Here’s What Happened

Shares of Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) rose 16.9% during mid-day trading on Thursday . The company traded as high as $1.04 and last traded at $0.97. Approximately 750,755 shares were traded during trading, an increase of 408% from the average daily volume of 147,756 shares. The stock had previously closed at $0.8299.

Analyst Upgrades and Downgrades

Separately, D. Boral Capital reiterated a “buy” rating and issued a $9.00 target price on shares of Kairos Pharma in a research note on Wednesday, November 19th. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average target price of $8.33.

Kairos Pharma Price Performance

The firm has a fifty day moving average of $0.80 and a two-hundred day moving average of $1.01. The stock has a market capitalization of $18.32 million, a P/E ratio of -2.84 and a beta of 2.28.

Kairos Pharma (NYSEAMERICAN:KAPA) last posted its earnings results on Friday, November 14th. The company reported ($0.07) EPS for the quarter.

Institutional Trading of Kairos Pharma

A number of hedge funds have recently bought and sold shares of the stock. FNY Investment Advisers LLC purchased a new position in shares of Kairos Pharma in the 3rd quarter valued at $27,000. Two Sigma Investments LP purchased a new stake in shares of Kairos Pharma during the third quarter valued at about $54,000. Finally, XTX Topco Ltd bought a new stake in shares of Kairos Pharma in the 2nd quarter valued at about $44,000.

About Kairos Pharma

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.